Suven Life Sciences Preferential Issue

Suven Life Sciences Q2 FY27 Results: Net Loss of ₹106.9 Cr, Loss Widens

Suven Life Sciences Ltd reported revenue from operations of ₹1.2 Cr (+33.3% YoY) and a net loss of ₹106.9 Cr for Q2 FY27.

Key figure

Net loss ₹106.9 Cr

Suven Life Sciences Board Meeting Date

Suven Life Sciences scheduled its board meeting for 5 November 2026 to approve Q1 and H1 FY27 unaudited results. The trading window closed from 1 October 2026 until 48 hours post-declaration.

Suven Life Sciences Other Announcement

Suven Life Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, pursuant to SEBI regulations.

Suven Life Sciences Business Update

Suven Life Sciences has completed patient enrollment for its global Phase-3 clinical study of Masupirdine. A total of 424 patients were randomized across the USA and Europe.

clinical trial enrollment

424.0 patients

Suven Life Sciences Annual General Meeting

Suven Life Sciences held its 37th Annual General Meeting on August 25, 2026. The company submitted the proceedings, scrutineer's report, and voting results.

Suven Life Sciences Other Announcement

Suven Life Sciences Limited submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report confirms the utilization of Rs. 857.64 Crore raised via preferential issue.

Value

₹857.6 Cr

IIFL Finance Preferential Issue

IIFL Finance's EGM on 4 December 2026 seeks approval for a preferential issue. Convertible preference shares and warrants total about ₹6,414.20 Crore.

Value

₹6,414 Cr

Natural Capsules Preferential Issue

Natural Capsules added an allotment of 1,12,500 equity shares and 4,50,000 warrants to promoter Sunil Mundra to its 13 November board agenda. No issue price is stated.

IIFL Finance Preferential Issue

IIFL Finance executed three subscription agreements for a preferential issue of CCPS and warrants at Rs 602 per share. Completion is subject to shareholder and regulatory approvals.

Simplex Infrastructures Preferential Issue

Simplex Infrastructures submitted the CARE Ratings monitoring agency report for the quarter ended 30 September 2026 on its preferential issue. The report shows nil deviation from objects, with the issue aggregating Rs.423.69 crore.

Bajaj Finance Preferential Issue

Bajaj Finance allotted preferential securities, with warrants and ESOPs converting to equity. Promoter Bajaj Finserv would hold 51.23% fully diluted at Rs 1,010 per share.

Shiva Granito Export Preferential Issue

Shiva Granito Export Ltd disclosed e-voting and scrutinizer results for its EGM held 5 November 2026. Three special resolutions passed, including a preferential issue of 54,50,000 equity shares and 35,00,000 fully convertible warrants.